As per last concall, the USFDA approvals would need upto 15/20cr. Clinical trials itself cost 2 mil. This would be needed over the period of 2 yrs. My guess is that the additional money would be for acquisition. Let’s hear that from management during concall whenever it gets scheduled.

I do have following additional questions, putting it across so that we can collaborate and ask questions whoever gets opportunity during con call.1. What do we plan to do with additional capital being raised?2. What is the progress on registration process with USFDA?3. B2C – what is the progress, when can we start recognizing sales. What is overall strategy, branding, distribution plan etc4. On Govt of South Africa order, how much of that is now remaining to be delivered in Q4 & fy18?5. Regarding repeat order from Govt of South Africa, we had following update from earlier conf call.We have several round of meeting. Their deadline is Dec 17. June 18 is current tender. They may increase by 40% more.any further update on it?6. During Jan to mar we expect more tenders to come out which would be for fy18/fy19. How is the tender pipeline looking and anything that we are winning from it?

Another interesting point I have,Normally, the cupid management immediately announces the conf call with the investor community, i.e just after the quarterly results.This time , they have specifically asked for some more time in the press release.Something is definitely cooking here !!I hope -Maybe new ceo ?- large new order ?- acquisition ?My point is , apart from a major development expected by the management, there is no logical reason why the investor conf call should be delayed indefinetely.

No, have not had any recent interaction with the mgt. I do not have much to add to my posts of Jan 5th & 6th. I guess the next concall will happen only after the mgt. is in a position to share with us who the incoming institutional investors are & how exactly do the intend to use the funds that are coming in.

What a great thread and what learning! super really really enjoyed going through each of the 575 posts.

After going through , i have come to believe that Cupid has transitioned to a "Franchise". In his 1991 letter WEB laid down his definition of franchise and i believe Cupid fits the bill. He says

An economic franchise arises from a product or service that: (1) is needed or desired; (2) is thought by its customers to have no close substitute and; (3) is not subject to price regulation.

The existence of all three conditions will be demonstrated by a company's ability to regularly price its product or service aggressively and thereby to earn high rates of return on capital.

There is no question that FC's are needed

The YWCA (a global organization working for the empowerment, leadership and rights of women, young women and girls in more than 120 countries) says that "Female condoms remain the only tool for HIV prevention that women can initiate and control". In other words - there is no substitute for a female condom especially when it comes to preventing HIV.

There are no price regulations.

Cupid has managed to increase its price realization by a significant amount thereby demonstrating its capacity to raise prices. Its raw material cost (latex) was only 36% of its sales in 2016. In 2013, it was 61%. While latex raw material prices have come down to Rs 8455 per 100 kg in March 16 from Rs 11,100 per 100 kg - translating to a drop of 24% ( source: http://rubberboard.org.in/rubberprice.asp?url=earlyrubberprice.asp). There is undeniable evidence that Cupid has managed to increase prices ( even if we price raw material cost to 2013 levels)

Over the last two stellar years 2015 & 2016, the company has managed to deploy an addn 11.9cr of equity producing an incremental profit of 8.2 cr. This translates to a superb incremental return on incremental equity of 69%. They have done this by reinvesting only 50% of the earnings. This means that the expected earnings growth rate going forward if they manage to keep up with this is a remarkable 34.8%.

The company has improved its capital turns ( from 1.92 to 2.2 ) and the margins have expanded ( from 17% to 26% ). Both have improved substantially.

It seems to be that at a PE of ~18 the market is completely ignoring its growth prospects. Any growth over any period will lead to a rerating again. I am invested and obviously biased ( came to the party late , read through all the posts , stock corrected dramatically and offered me a chance to get on the bus full of happy investors )

And for those who are interested, here is the original patent granted in 1989 ( filed for in 1982 ) for the invention of the female condom to its inventor Henry J. Lee. FC's were invented 35 years ago !

While I love the financial ratios and growth figures of this company, what I worry the most is this - one man (Owner) show , one product (FC) company. Any "Black Swan" event can deal a severe blow to this company. So personally I feel risks are far outweighing the upside potential (maybe after reading Howard Marks memos)

"There are still more than 225 _million women in the developing world who dont want to get pregnant but dont have access to contraceptives"_

Melinda: Family Planning 2020, a global partnership that we’re a part of, has set a goal of providing 120 million more women access to contraceptives by 2020. We’re focusing on South Asia, where contraceptives are used by only a third of the women, and on Africa—where they’re used by fewer than one in five.